Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Metab Brain Dis. 2013 Jun;28(2):321-6. doi: 10.1007/s11011-013-9388-0. Epub 2013 Mar 6.
There is a strong relationship between liver and gut; while the portal venous system receives blood from the gut, and its contents may affect liver functions, liver in turn, affects intestinal functions through bile secretion. There is robust evidence that the pathogenesis of hepatic encephalopathy (HE) is linked to alterations in gut microbiota and their by-products such as ammonia, indoles, oxindoles, endotoxins, etc. In the setting of intestinal barrier and immune dysfunction, these by-products are involved in the pathogenesis of complications of liver cirrhosis including HE and systemic inflammation plays an important role. Prebiotics, probiotics and synbiotics may exhibit efficacy in the treatment of HE by modulating the gut flora. They improve derangement in flora by decreasing the counts of pathogenic bacteria and thus improving the endotoxemia, HE and the liver disease. Current evidence suggest that the trials evaluating the role of probiotics in the treatment of HE are of not high quality and all trials had high risk of bias and high risk of random errors. Therefore, the use of probiotics for patients with HE cannot be currently recommended. Further RCTs are required. This review summarizes the main literature findings about the relationships between gut flora and HE, both in terms of the pathogenesis and the treatment of HE.
肝脏和肠道之间存在着密切的关系;门静脉系统从肠道接收血液,其内容物可能会影响肝脏功能,而肝脏反过来又通过胆汁分泌影响肠道功能。有强有力的证据表明,肝性脑病(HE)的发病机制与肠道微生物群及其代谢产物(如氨、吲哚、氧化吲哚、内毒素等)的改变有关。在肠道屏障和免疫功能障碍的情况下,这些代谢产物参与了肝硬化并发症的发病机制,包括 HE 和全身炎症发挥重要作用。益生菌、益生元和合生菌可能通过调节肠道菌群对 HE 的治疗有效。它们通过减少致病菌的数量来改善菌群失调,从而改善内毒素血症、HE 和肝病。目前的证据表明,评估益生菌治疗 HE 作用的试验质量不高,所有试验均存在偏倚风险高和随机误差风险高的问题。因此,目前不能推荐使用益生菌治疗 HE 患者。需要进一步的 RCT 研究。本综述总结了关于肠道菌群与 HE 之间关系的主要文献发现,包括 HE 的发病机制和治疗。